First healthy volunteer dosed with C106 in a phase 1 trial
C106 is the first new angiotensin II type 2 receptor agonist (ATRAG) from Vicore's VP03 program
Topline data expected Q1 2023
GOTHENBURG, Sweden, June 16, 2022 /PRNewswire/ -- Vicore Pharma Holding AB (publ) ("Vicore"), a clinical-stage pharmaceutical company developing medicines targeting the angiotensin II type 2 receptor (AT2R), today announcesinitiation of a first-in-human trial with the novel ATRAG C106.
